Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Status:
Withdrawn
Trial end date:
2006-09-05
Target enrollment:
Participant gender:
Summary
Primary Objective:
To determine the safety and efficacy of Campath-1H (Alemtuzumab) in patients with relapsed
and resistant classical Hodgkin's lymphoma.
Secondary Objectives:
1. To determine the duration of response and time to progression after Campath-1H therapy
in this patient population.
2. To determine the effect of Campath-1H on serum IL-6, IL-10, and IL-13 levels in patients
with relapsed and resistant classical Hodgkin's lymphoma.